Individual Lab Report Ci-Trol Nov,2016. Abnormal Fibrinogen (mg/dl) Abnormal Fbg Control - Lot# LFC Your Lab

Similar documents
Worldwide Report Coagulation Lot Exp 31 Oct 2018

Method Comparison Report Semi-Annual 1/5/2018

INTERNAL QUALITY CONTROL ( Q I C) QC)

Determination of APTT factor sensitivity the misguiding guideline

Guide to Fulfillment of Measurement Uncertainty

QUANTIFYING THE EFFECT OF SETTING QUALITY CONTROL STANDARD DEVIATIONS GREATER THAN ACTUAL STANDARD DEVIATIONS ON WESTGARD RULES

METHOD VALIDATION CASE

Cardiac Assessment Controls

Use of PSI on CS instruments

Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation

USING THE ACCESS AMH ASSAY IN YOUR LABORATORY

METHOD VALIDATION CASE

Setting of quality standards

Presented by Marcelo Cardona, MT(ASCP) Johns Hopkins University

Y. ZHAO, G. LV SUMMARY

Polymer Technology Systems, Inc. CardioChek PA Comparison Study

A validation study of after reconstitution stability of diabetes: level 1 and diabetes level 2 controls

Patricia C. Fallest-Strobl, 1 Elin Olafsdottir, 2 Donald A. Wiebe, 1 and James O. Westgard 1 * Lipoproteins

College of American Pathologists (CAP) GH2 Survey Data: (updated 12/09) 2009 GH2-B (fresh pooled samples) * = NGSP certified at the time of the survey

LOGO. Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University & Thai Society of Clinical Pathology

Use of PSI on CS instruments

Evaluation of the Precision and Accuracy of the INRatio 2 Prothrombin Time (PT) Monitoring System

Two Important Statistics

METHOD VALIDATION: WHY, HOW AND WHEN?

Forum for Collaborative HIV Research External Validation of CD4 and Viral Load Assays Paris, France June 29, 2007

Bio-Rad Laboratories. Cardiac Assessment Controls. Value Assigned for Clinical Laboratory and Point of Care Test Systems

Determination of hemoglobin is one of the most commonly

NICO /14 Nipro Diagnostics, Inc.

(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)

Accuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips

Insights on the Quality of Coagulation Testing

Recommended Additional EUA QC checks for Zika MAC-ELISA. Wendi Kuhnert, PhD Co-Lead, Zika Laboratory Task Force

Technical Bulletin. Cholesterol Reference Method Laboratory Network (CRMLN) Overview. TB Rev. 0

CLINITEK Novus Automated Urine Chemistry Analyzer

The analytical phase

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26

EQAS. Hemoglobin Program (BC80) Cycle 12: December 2014 December 2015 Sample No: 1 Sample Date: 17 Dec 14. Exceptions. Customer Information

Uncertainty vs. total error in judging performance of participants Milano th International Meeting, CIRME

Evaluation Report: Eurolyser CRP test (ST0100 and ST0102) on. CUBE analyser (CA0100)

Hemostasis Test Validation, Performance and Reference Intervals

Farouk AL Quadan lecture 3 Implentation of

HEMOCHRON. Whole Blood Coagulation Systems

Third Party Controls for Your Dade Behring Systems

Week 17 and 21 Comparing two assays and Measurement of Uncertainty Explain tools used to compare the performance of two assays, including

How Good is your INR? The Use of Certified Plasmas in PT/INR Testing. INR System. How Good is your INR? Outline

CCQM-K11: Key Comparison on the Determination of Total Glucose in Human Serum. Final Report May 2003

Cardiac Assessment Controls A critical element of reliable cardiac testing

GlucoMen LX PLUS blood glucose and blood ketone meter. Accuracy Evaluation to New ISO 15197:2013, with Technical and Specification Data

SQA-V Gold Semiannual Validation/Proficiency/QC Recommendations

Accuracy and Precision Performance of the Accu-Chek Mobile System. Introduction. Method

Multicenter evaluation of the CoaguChek Prothrombin Time (PT) Test on the CoaguChek Pro II meter White paper

Basic knowledge of POCT instuments. The Tide Resort Bangsan Beach 18 June 2009

1. PROTOCOL. Comparison Study Summary. Tuality Healthcare 324 SE 9 th Ave. Suite E Hillsboro, OR July 30, 2014

System accuracy evaluation of FORA Test N Go Blood Glucose Monitoring System versus YSI 2300 STAT Plus glucose analyzer following ISO 15197:2013

White Paper, Evaluation of WaveSense JAZZ Blood Glucose Monitoring System Analytical Performance to EN ISO 15197:2015 Standard

FreeStyle Lite A Blood Glucose Meter That Requires No Coding

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27

Customer Bulletin. Questions/Comments? Please call Customer Service at (Direct) or (Toll-free inside USA).

Equivalent Accuracy Evaluation of FORA Premium V10 Blood Glucose Monitoring System as Compared to Fora V30 Blood Glucose Monitoring System

Performance Guide. icheck Iodine The test kit to measure iodine in salt

Rethinking Traditional Lab QA/QC:

1 PROTOCOL. Comparison Study Summary

The Virtues and Pitfalls of Implementing a New Test

PointCare NOW TM Technical Note

URGENT FIELD SAFETY NOTICE IMMEDIATE ACTION REQUIRED

1 PROTOCOL. Comparison Study Summary. Springs Memorial Hospital. Springs Memorial Hospital 800 W. Meeting St. Lancaster, SC (803)

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

ImmunoCAP Systems. Optimized for allergy testing - Precision - Accuracy - Consistency

The Whats and Hows of Reference Intervals. Graham Jones Department of Chemical Pathology St Vincent s Hospital, Sydney

2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance

AOAC Research Institute Performance Tested Methods SM Program. Measurement of Free Fatty Acids Using FASafe Standard Test Kit. Certificate Report

Proficiency Testing Evaluation

GlucCell TM SYSTEM USER S GUIDE ver 2.3 CELL CULTURE GLUCOSE METER. Important Information. Intended Use. Caution. About the System

Multiple studies are available concerning the use of

liquicolor (AMP Buffer, IFCC) Design Verification

P re-analytical conditions are very important in laboratory assessment of hemostatic and coagulation systems

Comparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used in Coagulation Testing

Annual Report ERNDIM-EQAS Quantitative Amino Acids 2004

Commentary by R. Little, Ph.D., NGSP Network Coordinator for the NGSP Steering Committee

Clinical Performance of the TRUE2go Blood Glucose Monitoring System Exceeds Minimum Criteria for Accuracy Using ISO 15197:2013

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

C. Bachmann This article was published as. Centre Hospitalier Universitaire Vaudois Number 3 in May 2000 CH 1011 Lausanne, Switzerland

Quality Specifications for POCT

Commentary by R. Little, Ph.D., NGSP Network Coordinator for the NGSP Steering Committee

BLOOD GLUCOSE METERS ACCURACY REQUIREMENTS

Rethinking Tradi.onal QA/QC: Weaknesses of Current Prac.ces; Six Sigma Metrics and Tools for Improvement

System accuracy evaluation of FORA Test N Go Blood Glucose Monitoring System versus YSI 2300 STAT Plus glucose analyzer following ISO 15197:2013

Four rules to remember: 1) Addition, subtraction, multiplication and division of SD and/or CV.

TRENDS IN TIME. EXTERNAL EVALUATION PROGRAM FOR Immmunoassays - Chemistry

Annual Report ERNDIM-EQAS Quantitative Amino Acids 2002

Evaluation Report. Eurolyser PT (INR) test kit (ST0180) on CUBE and smart analysers

Confirmation - A Practical Approach

Certificate of Analysis

" EXTERNAL QUALITY EVALUATION PROGRAM FOR POCT GLUCOSE TESTING years of experience

Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

4/10/2017. Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

Agenda. 15 Dec

Selecting a Risk-Based SQC Procedure for a HbA1c Total QC Plan

LIPASE liquicolor. Design Verification. Multipurpose Reagent

Transcription:

Individual Lab Report Ci-Trol Nov,2016 ST VINCENT MEDICAL CENTER LABORATORY(LAB# 7300 ) 2131 WEST THIRD STREET LOS ANGELES CA USA 90057 Abnormal Fibrinogen (mg/dl) Abnormal Fbg Control - Lot# LFC SYSMEX CA 1500-1, DADE THROMBIN Nov 109.3 7.00 6.4 11 105.5 5.33 5.0 134 SYSMEX CA 1500/7000, DADE THROMBIN Period Avg. SD Avg. CV s # Points SDI CVI Nov 109.8 1 5.52 4.9 8 245-0.1 1.3 110.1 3.97 5.3 69 24790-1.2 1.0 Nov 110.8 6.09 4.6 12 348-0.2 1.4 110.5 4.53 5.4 92 34097-1.1 0.9 1. Individual means in peer 109.900, 116.600, 119.000, 105.462, 102.417, 108.431, 107.217, 109.300 Abnormal Fbg Control - Lot# LFC SYSMEX CA 1500-2, DADE THROMBIN Nov 106.0 N N 3 101.5 4.35 4.3 109 SYSMEX CA 1500/7000, DADE THROMBIN Period Avg. SD Avg. CV s # Points SDI CVI Nov 109.8 1 5.52 4.9 8 245-0.7 0.2 110.1 3.97 5.3 69 24790-2.2 0.8 Nov 110.8 6.09 4.6 12 348-0.8 0.3 110.5 4.53 5.4 92 34097-2.0 0.8 1. Individual means in peer 109.900, 116.600, 119.000, 105.462, 102.417, 108.431, 107.217, 109.300 APTT (seconds) Ci-Trol 1 - Lot# 548015 SYSMEX CA 1500-1, DADE ACTIN FSL Nov - N - - 25.9 0.42 1.6 845 SYSMEX CA 1500/7000, DADE ACTIN FSL Period Avg. SD Avg. CV s # Points SDI CVI Nov 25.3 1 0.22 2.0 6 418 - - 25.5 0.44 1.9 103 78095 0.8 0.9 1. Individual means in peer 25.300, 25.230, 25.530, 25.490, 25.021, 25.000 Nov 25.1 0.44 2.1 14 857 - - 25.3 0.49 2.1 260 191977 1.1 0.8 SYSMEX CA 1500-1, DADE ACTIN FSL Nov 60.3 1.21 2.0 55 59.8 1.34 2.2 924 SYSMEX CA 1500/7000, DADE ACTIN FSL Period Avg. SD Avg. CV s # Points SDI CVI Nov 59.2 1 1.06 2.2 8 546 1.0 0.9 59.7 1.07 2.3 102 78351 0.1 1.0 Nov 56.7 3.73 2.0 17 1005 1.0 1.0 57.4 2.99 2.5 262 194061 0.8 0.9 1. Individual means in peer 57.800, 58.430, 60.210, 60.010, 58.280, 58.480, 60.300, 60.200 Total Error Graph (= ) CLIA 132.180 105.517 CLIA 88.120 Total Error Graph (= ) CLIA 132.180 101.459 CLIA 88.120 Total Error Graph (= ) CLIA 29.340 25.868 CLIA 21.686 Total Error Graph (= ) CLIA 68.640 59.829 CLIA 50.734 Refer to the Siemens Hemostasis QAP Report Appendix for report definitions and calculations. Print Date & Time: 27-Jul-18 6:42:39 AM Part No.: D53852 Page: 1

Individual Lab Report Ci-Trol Nov,2016 ST VINCENT MEDICAL CENTER LABORATORY(LAB# 7300 ) 2131 WEST THIRD STREET LOS ANGELES CA USA 90057 APTT (seconds) SYSMEX CA 1500-2, DADE ACTIN FSL Nov 60.2 0.77 1.3 34 60.3 1.85 3.1 952 SYSMEX CA 1500/7000, DADE ACTIN FSL Period Avg. SD Avg. CV s # Points SDI CVI Nov 59.2 1 1.06 2.2 8 546 0.9 0.6 59.7 1.07 2.3 102 78351 0.6 1.3 Nov 56.7 3.73 2.0 17 1005 0.9 0.6 57.4 2.99 2.5 262 194061 1.0 1.2 1. Individual means in peer 57.800, 58.430, 60.210, 60.010, 58.280, 58.480, 60.300, 60.200 Clauss Fibrinogen (mg/dl) Ci-Trol 1 - Lot# 548015 SYSMEX CA 1500-1, DADE THROMBIN Nov - N - - 247.2 8.10 3.3 120 SYSMEX CA 1500/7000, DADE THROMBIN Period Avg. SD Avg. CV s # Points SDI CVI Nov 261.5 1 8.35 3.5 5 191 - - 257.8 7.25 4.2 74 27651-1.5 0.8 Nov 261.0 7.20 4.3 9 284 - - 261.0 12.15 4.5 101 36302-1.1 0.7 1. Individual means in peer 275.200, 263.800, 256.600, 255.865, 256.023 Prothrombin Time (seconds) Ci-Trol 1 - Lot# 548015 SYSMEX CA 1500-1, DADE INNOVIN Nov - N - - 10.7 0.22 2.0 844 SYSMEX CA 1500/7000, DADE INNOVIN Period Avg. SD Avg. CV s # Points SDI CVI Nov 11.0 1 0.14 2.2 6 436 - - 10.8 0.14 2.0 103 81577-0.7 1.0 1. Individual means in peer 11.000, 10.800, 11.060, 10.940, 11.150, 11.161 Nov 10.9 0.31 2.1 18 1014 - - 10.7 0.28 2.1 297 220172-0.1 1.0 SYSMEX CA 1500-1, DADE INNOVIN Nov 54.2 2.30 4.2 97 53.2 2.27 4.3 971 SYSMEX CA 1500/7000, DADE INNOVIN Period Avg. SD Avg. CV s # Points SDI CVI Nov 53.1 1 2.24 3.7 8 641 0.5 1.1 53.2 1.21 3.2 104 83097 0.0 1.3 Nov 52.8 1.84 3.4 19 1137 0.8 1.2 52.9 1.56 3.3 294 217987 0.2 1.3 1. Individual means in peer 48.900, 50.810, 53.490, 52.710, 54.485, 54.389, 54.200, 55.800 Total Error Graph (= ) CLIA 68.640 60.326 CLIA 50.734 Total Error Graph (= ) CLIA 309.307 247.225 CLIA 206.204 Total Error Graph (= ) CLIA 12.427 10.708 CLIA 9.185 Total Error Graph (= ) CLIA 61.221 53.234 CLIA 45.250 Refer to the Siemens Hemostasis QAP Report Appendix for report definitions and calculations. Print Date & Time: 27-Jul-18 6:42:39 AM Part No.: D53852 Page: 2

Individual Lab Report Ci-Trol Nov,2016 ST VINCENT MEDICAL CENTER LABORATORY(LAB# 7300 ) 2131 WEST THIRD STREET LOS ANGELES CA USA 90057 Prothrombin Time (seconds) SYSMEX CA 1500-2, DADE INNOVIN Nov 55.8 2.06 3.7 34 54.1 2.53 4.7 1108 SYSMEX CA 1500/7000, DADE INNOVIN Period Avg. SD Avg. CV s # Points SDI CVI Nov 53.1 1 2.24 3.7 8 641 1.2 1.0 53.2 1.21 3.2 104 83097 0.7 1.5 Nov 52.8 1.84 3.4 19 1137 1.6 1.1 52.9 1.56 3.3 294 217987 0.8 1.4 1. Individual means in peer 48.900, 50.810, 53.490, 52.710, 54.485, 54.389, 54.200, 55.800 Total Error Graph (= ) CLIA 61.221 54.061 CLIA 45.250 QAP Reports are designed primarily to summarize data on Siemens Hemostasis Controls. The Statistics are calculations from user input and are provided as a service to customers. No claim is made as to the validity of values, tests and methods beyond those specifically identified on Siemens Hemostasis Control inserts and product literature. Refer to the Siemens Hemostasis QAP Report Appendix for report definitions and calculations. Print Date & Time: 27-Jul-18 6:42:39 AM Part No.: D53852 Page: 3

Report Appendix DATA CODES Any code that may appear with data on Siemens Hemostasis QAP reports is listed here with a brief description. 1 This symbol prints next to the Avg when the number of peers in the peer group is 10 or fewer, signifying a small peer group. For these small sample sizes, the individual means of each peer in the group are printed at the end of the data for the control level. "-" This statistic was Not Calculated for the indicated data collection period due to the presence of incongruent data in the calculation. C This data has been changed or added by Siemens Hemostasis QAP at the request of your laboratory. G L N P S This value did not pass the Gross Outlier Check, which excludes extremely discrepent data that falls outside of present limits for each test. This data was not processed and is not included in QAP Reports. This value did not pass the Laboratory Outlier Check, which excludes values more than +/- 3 standard deviations from the lab s mean for the month. This value was excluded from the calculation of the lab s mean and SD for this month. The SD and CV for a set of control data points for an individual lab are not displayed when the number of points for the set is less than five. Your lab s mean did not pass the Outlier Check, which excludes lab means from peer statistics that are discrepant from the average peer mean. Your lab s All Shift mean did not pass the Outlier Check, which excludes lab means from peer statistics that are discrepent from the average peer mean. Data from all shifts has been excluded from the peer statistics. DEFINITIONS Avg. CV CVI The peer average mean is calculated by averaging the individual means in a peer group. Comparing the lab mean to the peer average can aid in evaluating analytical accuracy. The coefficient of variation is the SD expressed as a percentage of the mean and is calculated by dividing the SD by the mean and multiplying by 100. It is useful in evaluating precision. The coefficient of variation index compares the lab s CV to the peer group median CV for evaluating precision. The CVI calculation is: Lab CV Average CV Avg. CV Lot-to-Date describes a data collection period which includes all QC data received thus far for this control lot, either for the lab or the peer, as indicated. The peer average CV (coefficient of variation) is calculated by averaging the individual CV s in a peer group. Comparing the lab CV to the peer average CV aids in evaluationg precision. Print Date & Time: 27-Jul-18 6:42:39 AM Part No.: D53865 Page: 1

Report Appendix For Chemistry tests, the statistics for this peer group category are calculated by combining data submitted from peers using the same method principle, with any instrument and reagent. For Hemostasis tests, the statistics for this peer group category are calculated by combining data submitted from peers using the same method principle and reagent, with any instrument. SD SD SDI The SD is the standard deviation (SD) of all the acceptable current or cumulative () lab means used in the calculation of the, or J&J Vitros standard deviation index (SDI). The standard deviation for a lab represents the spread of a set of individual data points around their mean. It is useful in evaluating precision. The standard deviation index compares the lab s mean to the peer group average mean for evaluating accuracy. The reports identify the peer group used in the SDI calculation. The SDI calculation is: Lab mean - Avg. SD Total Error (TE) The statistics for this peer group category are calculated by combinig data submitted from peers using the same or similarly performing instrumentation, and the same reagent and reaction temperature (when applicable). Total Error (TE) refers to the total analytical error of a lab s analytical method and may be used to assess its inaccuracy and imprecision. The Total Error Graph compares the Total Error of the lab s analytical method to the Total Error Limits (calculated using the mean). To assess the acceptability of the lab s Total Error, the lab s mean +/-2 SD range is compared to the Total Error Limits. This range should be within the Total Error Limits. The Total Error Limits are calculated using test performance guidelines from one of the following: U.S. CLIA, Medical Society of Germany or +/- 3 SD. Using these guidelines, the lower and upper limits are established with this calculation: the Average +/- test specific guidelines. When such guidelines are not available, the limits are not calculated. When a Total Error Limit is exceeded, it may be necessary to investigate for sources of either inaccuracy or imprecision. While this information may assist with predicting proficiency testing performance due to peer and methodological differences, it is suggested that discretion be used in interpretation. In addition, the lab must define its own analytical goals for minimizing bias and imprecision, and medical decision levels. Print Date & Time: 27-Jul-18 6:42:39 AM Part No.: D53865 Page: 2